Oxidative stress and tardive dyskinesia

Pharmacogenetic evidence

Chul Hyun Cho, Heon-Jeong Lee

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Tardive dyskinesia (TD) is a serious adverse effect of long-term antipsychotic use. Because of genetic susceptibility for developing TD and because it is difficult to predict and prevent its development prior to or during the early stages of medication, pharmacogenetic research of TD is important. Additionally, these studies enhance our knowledge of the genetic mechanisms underlying abnormal dyskinetic movements, such as Parkinson's disease. However, the pathophysiology of TD remains unclear. The oxidative stress hypothesis of TD is one of the possible pathophysiologic models for TD. Preclinical and clinical studies of the oxidative stress hypothesis of TD indicate that neurotoxic free radical production is likely a consequence of antipsychotic medication and is related to the occurrence of TD. Several studies on TD have focused on examining the genes involved in oxidative stress. Among them, manganese superoxide dismutase gene Ala-9Val polymorphisms show a relatively consistent association with TD susceptibility, although not all studies support this. Numerous pharmacogenetic studies have found a positive relationship between TD and oxidative stress based on genes involved in the antioxidant defense mechanism, dopamine turnover and metabolism, and other antioxidants such as estrogen and melatonin. However, many of the positive findings have not been replicated. We expect that more research will be needed to address these issues.

Original languageEnglish
Pages (from-to)207-213
Number of pages7
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume46
DOIs
Publication statusPublished - 2013 Oct 1

Fingerprint

Pharmacogenetics
Oxidative Stress
Antipsychotic Agents
Tardive Dyskinesia
Antioxidants
Genes
Dyskinesias
Melatonin
Genetic Predisposition to Disease
Research
Superoxide Dismutase
Free Radicals
Parkinson Disease
Dopamine
Estrogens

Keywords

  • Oxidative stress
  • Pharmacogenetics
  • Tardive dyskinesia

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

Oxidative stress and tardive dyskinesia : Pharmacogenetic evidence. / Cho, Chul Hyun; Lee, Heon-Jeong.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 46, 01.10.2013, p. 207-213.

Research output: Contribution to journalArticle

@article{66ce5530671247fd8d49b2baee91e94e,
title = "Oxidative stress and tardive dyskinesia: Pharmacogenetic evidence",
abstract = "Tardive dyskinesia (TD) is a serious adverse effect of long-term antipsychotic use. Because of genetic susceptibility for developing TD and because it is difficult to predict and prevent its development prior to or during the early stages of medication, pharmacogenetic research of TD is important. Additionally, these studies enhance our knowledge of the genetic mechanisms underlying abnormal dyskinetic movements, such as Parkinson's disease. However, the pathophysiology of TD remains unclear. The oxidative stress hypothesis of TD is one of the possible pathophysiologic models for TD. Preclinical and clinical studies of the oxidative stress hypothesis of TD indicate that neurotoxic free radical production is likely a consequence of antipsychotic medication and is related to the occurrence of TD. Several studies on TD have focused on examining the genes involved in oxidative stress. Among them, manganese superoxide dismutase gene Ala-9Val polymorphisms show a relatively consistent association with TD susceptibility, although not all studies support this. Numerous pharmacogenetic studies have found a positive relationship between TD and oxidative stress based on genes involved in the antioxidant defense mechanism, dopamine turnover and metabolism, and other antioxidants such as estrogen and melatonin. However, many of the positive findings have not been replicated. We expect that more research will be needed to address these issues.",
keywords = "Oxidative stress, Pharmacogenetics, Tardive dyskinesia",
author = "Cho, {Chul Hyun} and Heon-Jeong Lee",
year = "2013",
month = "10",
day = "1",
doi = "10.1016/j.pnpbp.2012.10.018",
language = "English",
volume = "46",
pages = "207--213",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Oxidative stress and tardive dyskinesia

T2 - Pharmacogenetic evidence

AU - Cho, Chul Hyun

AU - Lee, Heon-Jeong

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Tardive dyskinesia (TD) is a serious adverse effect of long-term antipsychotic use. Because of genetic susceptibility for developing TD and because it is difficult to predict and prevent its development prior to or during the early stages of medication, pharmacogenetic research of TD is important. Additionally, these studies enhance our knowledge of the genetic mechanisms underlying abnormal dyskinetic movements, such as Parkinson's disease. However, the pathophysiology of TD remains unclear. The oxidative stress hypothesis of TD is one of the possible pathophysiologic models for TD. Preclinical and clinical studies of the oxidative stress hypothesis of TD indicate that neurotoxic free radical production is likely a consequence of antipsychotic medication and is related to the occurrence of TD. Several studies on TD have focused on examining the genes involved in oxidative stress. Among them, manganese superoxide dismutase gene Ala-9Val polymorphisms show a relatively consistent association with TD susceptibility, although not all studies support this. Numerous pharmacogenetic studies have found a positive relationship between TD and oxidative stress based on genes involved in the antioxidant defense mechanism, dopamine turnover and metabolism, and other antioxidants such as estrogen and melatonin. However, many of the positive findings have not been replicated. We expect that more research will be needed to address these issues.

AB - Tardive dyskinesia (TD) is a serious adverse effect of long-term antipsychotic use. Because of genetic susceptibility for developing TD and because it is difficult to predict and prevent its development prior to or during the early stages of medication, pharmacogenetic research of TD is important. Additionally, these studies enhance our knowledge of the genetic mechanisms underlying abnormal dyskinetic movements, such as Parkinson's disease. However, the pathophysiology of TD remains unclear. The oxidative stress hypothesis of TD is one of the possible pathophysiologic models for TD. Preclinical and clinical studies of the oxidative stress hypothesis of TD indicate that neurotoxic free radical production is likely a consequence of antipsychotic medication and is related to the occurrence of TD. Several studies on TD have focused on examining the genes involved in oxidative stress. Among them, manganese superoxide dismutase gene Ala-9Val polymorphisms show a relatively consistent association with TD susceptibility, although not all studies support this. Numerous pharmacogenetic studies have found a positive relationship between TD and oxidative stress based on genes involved in the antioxidant defense mechanism, dopamine turnover and metabolism, and other antioxidants such as estrogen and melatonin. However, many of the positive findings have not been replicated. We expect that more research will be needed to address these issues.

KW - Oxidative stress

KW - Pharmacogenetics

KW - Tardive dyskinesia

UR - http://www.scopus.com/inward/record.url?scp=84883550642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883550642&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2012.10.018

DO - 10.1016/j.pnpbp.2012.10.018

M3 - Article

VL - 46

SP - 207

EP - 213

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

ER -